UFT plus calcium folinate plus radiotherapy for recurrent rectal cancer

Area of Science:

• Oncology
• Clinical Pharmacology
• Radiation Oncology

Background:

• Recurrent rectal cancer presents a significant clinical challenge.
• Orzel, an oral agent comprising uracil and tegafur (UFT) with calcium folinate, shows promise comparable to intravenous 5-fluorouracil.
• Combination therapy with radiation is a standard approach for rectal cancer, but optimal oral regimens require investigation.

Purpose of the Study:

• To design and describe an open-label, disease-oriented Phase I clinical trial.
• To evaluate the safety and tolerability of UFT plus calcium folinate in combination with simultaneous pelvic radiation.
• To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of this combined-modality regimen.

Main Methods:

• Open-label, Phase I clinical trial design.
• Recurrent rectal cancer patient population.
• Dose escalation methodology to determine MTD and DLTs.
• Combination of oral UFT/calcium folinate with simultaneous pelvic radiation therapy.

Main Results:

• This section describes the trial design; results are pending study completion.
• The study is designed to establish safety parameters for the investigational regimen.
• Identification of MTD and DLTs will guide future therapeutic strategies.

Conclusions:

• The described Phase I trial is crucial for evaluating a novel oral chemoradiation regimen for recurrent rectal cancer.
• Establishing the safety profile and MTD is a prerequisite for further clinical development.
• This research aims to optimize treatment options for patients with recurrent rectal cancer.